Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

5.500 +0.120 (+2.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Altimmune's Earnings ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
What's Going On With Altimmune (ALT) Stock Today? ↗
Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress. 
Via Benzinga
News headline image
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? ↗
Via The Motley Fool
News headline image
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
News headline image
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
8 Analysts Assess Altimmune: What You Need To Know ↗
 
Via Benzinga
News headline image
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move ↗
Via The Motley Fool
News headline image
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon ↗
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved. 
Via Stocktwits
News headline image
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders ↗
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits. 
Via Benzinga
News headline image
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Decoding 4 Analyst Evaluations For Altimmune ↗
 
Via Benzinga
News headline image
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print ↗
The company plans to unveil details at its virtual R&D Day on March 13. 
Via Stocktwits
News headline image
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore ↗
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
News headline image
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users. 
Via MarketBeat
News headline image
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
News headline image
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
News headline image
3 Promising Biotech Stocks for the Long-Term: August 2024 ↗
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few. 
Via InvestorPlace
News headline image
The 7 Best Under $10 Stocks to Buy in August 2024 ↗
Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10. 
Via InvestorPlace
News headline image
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year ↗
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.